These authors showed CYP1B1 to be correlated with tumor grade, clinical stage, immune cell subtype infiltration, tumor mutation burden, and DNA sequence microsatellite instability, as well as therapeutic resistance. The gene discussed is CYP1B1; the disease is neoplasm.